DE60315664D1 - Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten - Google Patents

Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten

Info

Publication number
DE60315664D1
DE60315664D1 DE60315664T DE60315664T DE60315664D1 DE 60315664 D1 DE60315664 D1 DE 60315664D1 DE 60315664 T DE60315664 T DE 60315664T DE 60315664 T DE60315664 T DE 60315664T DE 60315664 D1 DE60315664 D1 DE 60315664D1
Authority
DE
Germany
Prior art keywords
sub
oxazol
preparing
benzoic acid
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315664T
Other languages
English (en)
Inventor
Michael R Reeder
Rick J Imbordino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Application granted granted Critical
Publication of DE60315664D1 publication Critical patent/DE60315664D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
DE60315664T 2002-06-20 2003-06-20 Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten Expired - Lifetime DE60315664D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39028502P 2002-06-20 2002-06-20
US45047803P 2003-02-27 2003-02-27
PCT/US2003/019585 WO2004000821A1 (en) 2002-06-20 2003-06-20 Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives

Publications (1)

Publication Number Publication Date
DE60315664D1 true DE60315664D1 (de) 2007-09-27

Family

ID=30003150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315664T Expired - Lifetime DE60315664D1 (de) 2002-06-20 2003-06-20 Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten

Country Status (18)

Country Link
US (2) US7115747B2 (de)
EP (1) EP1532123B1 (de)
JP (1) JP2005533811A (de)
CN (1) CN1324017C (de)
AT (1) ATE370131T1 (de)
AU (1) AU2003249344A1 (de)
BR (1) BR0312439A (de)
CA (1) CA2489988A1 (de)
CO (1) CO5670350A2 (de)
DE (1) DE60315664D1 (de)
EA (1) EA008389B1 (de)
HK (1) HK1081543A1 (de)
IL (1) IL165763A0 (de)
MX (1) MXPA04012630A (de)
NO (1) NO20045497L (de)
NZ (1) NZ537390A (de)
PL (1) PL374999A1 (de)
WO (1) WO2004000821A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351738B2 (en) * 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
TW200738701A (en) * 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
JP5274258B2 (ja) 2005-11-21 2013-08-28 アムジエン・インコーポレーテツド β−セクレターゼ調節物質及び使用方法
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US20080277393A1 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods
MX2009012608A (es) * 2007-05-25 2009-12-07 Amgen Inc Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
WO2008147547A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
WO2010030954A1 (en) 2008-09-11 2010-03-18 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
EP2504315A1 (de) 2009-11-23 2012-10-03 Amgen Inc. Aminoheteroarylverbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
US8822485B2 (en) 2009-11-23 2014-09-02 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
JP2013522305A (ja) 2010-03-15 2013-06-13 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのスピロ−四環式環化合物
ES2450568T3 (es) 2010-03-15 2014-03-25 Amgen Inc. Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US11272751B2 (en) 2016-03-01 2022-03-15 Nicholas Popejoy Protective headgear, impact diffusing systems and methods
US9462841B1 (en) 2016-03-01 2016-10-11 William Popejoy Protective headgear and shoulder pad apparatus and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
BR0213139A (pt) 2001-10-04 2004-08-10 Elan Pharm Inc Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
IL161881A0 (en) * 2001-11-08 2005-11-20 Upjohn Co N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EA008389B1 (ru) 2007-04-27
ATE370131T1 (de) 2007-09-15
BR0312439A (pt) 2005-05-10
AU2003249344A1 (en) 2004-01-06
WO2004000821A1 (en) 2003-12-31
US20070105921A1 (en) 2007-05-10
US7115747B2 (en) 2006-10-03
US20040063965A1 (en) 2004-04-01
EP1532123A1 (de) 2005-05-25
NO20045497D0 (no) 2004-12-16
CO5670350A2 (es) 2006-08-31
HK1081543A1 (en) 2006-05-19
NO20045497L (no) 2005-03-07
EP1532123B1 (de) 2007-08-15
EA200401510A1 (ru) 2005-06-30
CA2489988A1 (en) 2003-12-31
CN1662510A (zh) 2005-08-31
JP2005533811A (ja) 2005-11-10
PL374999A1 (en) 2005-11-14
NZ537390A (en) 2006-07-28
CN1324017C (zh) 2007-07-04
MXPA04012630A (es) 2005-09-30
IL165763A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
DE60315664D1 (de) Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten
ATE450523T1 (de) Verfahren zur herstellung von 3-halogen-4,5- dihydro-1 h-pyrazolen
JP2005502658A5 (de)
ATE404637T1 (de) Verbessertes verfahren und methode zur herstellung von asymmetrischen monofunktionalisierten indocyaninmarkern sowie erhaltene verbindungen
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
ATE441627T1 (de) Verfahren zur herstellung von valsartan
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
DE502005008867D1 (de) Verfahren zur herstellung von 2,5-dimethylphenylessigsäure
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE502004004970D1 (de) Verfahren zur herstellung von oh-geschützten ä4-(2,6-diamino-9h-purin-9-yl)-1,3-dioxolan-2-ylümethanol-derivaten
ATE157647T1 (de) Verfahren zur herstellung von alpha- ketoamidderivaten
ATE496907T1 (de) Verfahren zur herstellung von cilostazol
ATE415404T1 (de) Lösungsmittelfreies verfahren zur herstellung von diketopyrrolopyrrol-derivaten
ATE348811T1 (de) Verfahren zur herstellung von 2- aminomethylpyridin-derivaten
ATE282594T1 (de) Verfahren zur herstellung von (+)-trans-4-p- fluorophenyl-3-hydroxymethyl-1-methylpiperidin
ATE390400T1 (de) Verfahren zur herstellung von alpha'-chlorketonen
DE602005022213D1 (de) Verfahren zur herstellung von phenyl-2-pyrimidinyl-ketonen und neuen zwischenprodukten daraus
DE60306361D1 (de) Verfahren zur herstellung von benazeprilhydrochloride
WO2004032854A3 (en) Pharmaceutical compositions for treatment of parkinson's disease
DE60226879D1 (de) Verfahren zur herstellung von 4-(imidazol-1-yl)benzolsulfonamidderivaten
ATE223377T1 (de) Verfahren zur herstellung von difluoracetophenon- derivaten
ATE228512T1 (de) Verfahren zur herstellung von 3-isochromanonen durch cyclisierung von o- chlormehtylphenylessigsäuren
ATE339401T1 (de) Verfahren zur herstellung von alpha-(3-arylthio)- acetophenonen
DE60225338D1 (de) Verfahren zur herstellung von derivaten von 3,3-dimethyl-2-formylcyclopropanekarbonsäure
JP2006508158A5 (de)

Legal Events

Date Code Title Description
8332 No legal effect for de